Orchid BioSciences Inc. / AstraZeneca (Cellmark Diagnostics unit)

Forensic and paternity DNA identity testing

Disease Overview

This is not a disease deal — it is a genetic-identity diagnostics carve-out. Cellmark's services covered forensic DNA analysis for criminal investigations (UK police forces) and relationship/paternity testing using the original DNA fingerprinting technology developed by Sir Alec Jeffreys at the University of Leicester.

Competitive Landscape

In early 2001 the UK forensic DNA market was dominated by the government-owned Forensic Science Service (FSS), with Cellmark Diagnostics — then an AstraZeneca division — as the leading private competitor running services for police forces in England and Wales. The paternity-testing segment was fragmented across smaller private labs. Globally, the SNP-genotyping and DNA-identity testing space included Applied Biosystems (Celera/PE), Sequenom, Affymetrix, and Third Wave Technologies on the technology side, with Laboratory Corporation of America (LabCorp) and Quest Diagnostics holding strong US paternity-testing positions. Orchid BioSciences had built itself around its proprietary SNP-IT primer-extension genotyping platform but lacked a commercial DNA-identity services business at scale. Acquiring Cellmark from AstraZeneca gave Orchid an immediate, accredited UK forensic and paternity services franchise, established police-force contracts, and the original Jeffreys IP heritage. It was core enough to the new identity that the parent rebranded itself Orchid Cellmark, signaling the shift from a research-tools/SNP-genotyping company to a forensic-services operator. Financial terms were not disclosed at announcement; Orchid Cellmark was ultimately sold to LabCorp for $85.4M in 2011, indicating modest end-state franchise value.